Immunotherapy

The PD-1 inhibitor Opdivo (nivolumab) was granted accelerated approval for patients with unresectable or metastatic melanoma following treatment with Yervoy (ipilimumab) or a BRAF inhibitor.

The PD-1 inhibitor Keytruda (pembrolizumab) has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).

Debu Tripathy, editor-in-chief of CURE magazine, recaps the first day of the San Antonio Breast Cancer Symposium - namely the advances in treating breast cancer with immunotherapy.

Lee Greenberger, of the Leukemia & Lymphoma Society, explains how immunotherapy research has progressed in hematological cancers and the potential for these burgeoning therapies.

An early study in patients with Hodgkin lymphoma that had progressed on several lines of treatment found that the immunotherapy Keytruda (pembrolizumab) elicited a remarkable response.

A small phase 1 trial found that certain patients with classical Hodgkin lymphoma (cHL), who had previously failed three or more therapies, responded to the immunotherapy nivolumab.

The FDA approved the anti-CD19 immunotherapy Blincyto (blinatumomab) as a treatment for Philadelphia chromosome-negative acute lymphoblastic leukemia.

TheAnswerToCancer.org website offers information to patients solely about cancer immunotherapy.

Investigational vaccine appears to help progression-free survival and overall survival in patients with a type of glioblastoma.

Immunotherapy is coming of age not only in general oncology, but also in neuro-oncology.

With advances in screening strategies and targeted therapy for lung cancer, the arrival of immunotherapy looks to be the next big step in helping patients with the disease.

The FDA has granted a breakthrough therapy designation to the immunotherapy drug Keytruda (pembrolizumab) for the treatment of patients with non-small cell lung cancer.